Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

Fluorouracil 56Specimen Handling 51Oxaliplatin 49Leucovorin 46Magnetic Resonance Spectroscopy 45Bevacizumab 43Gemcitabine 39Irinotecan 30Cetuximab 27Nivolumab 25130-nm albumin-bound paclitaxel 25Cisplatin 24Biopsy 24pembrolizumab 22Paclitaxel 22Capecitabine 19atezolizumab 18durvalumab 14Taxes 14Folfox protocol 14Carboplatin 13X-Rays 12Radiotherapy 12Cyclophosphamide 12fludarabine 11dehydroftorafur 10Radiation 10Albumin-Bound Paclitaxel 10Surgical Procedures, Operative 9Immunoglobulin G 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
KP 1339 × Gastrointestinal × 30 days × Clear all
NCT04421820 2026-05-18

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Bold Therapeutics, Inc.

Phase 1/2 Recruiting
220 enrolled
Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡